ConvaTec Healthcare Postpones Plans To Refinance Secured Term Loans

SKILLMAN, New Jersey, March 17, 2011 - ConvaTec Healthcare, a world-leading developer, manufacturer and marketer
of innovative medical technologies for community and hospital care, today
announced that, following a review of current conditions in the credit
markets, it is postponing the refinancing of its senior secured term loans
originally entered into on December 22, 2010.

About ConvaTec

ConvaTec is a leading developer and marketer of innovative medical
technologies. With four key focus areas - Ostomy Care, Wound Therapeutics,
Continence and Critical Care, and Infusion Devices - ConvaTec products
support healthcare professionals from the hospital to the community health
setting. From its operational headquarters in Skillman, New Jersey, the
company conducts business in over 100 countries, serving consumers and their
health care professionals on six continents. For more information, please
visit www.convatec.com.

Certain statements in this press release are forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
Forward looking statements are all statements other than statements of
historical facts. Certain of these forward looking statements are identified
by terminology such as "aim," "anticipate," "believe," "continue," "could,"
"estimate," "expect," "forecast," "guidance," "intend," "may," "plan,"
"potential," "predict," "projected," "should," or "will" or the negative of
such terms or other comparable terminology. Others can be identified from the
context in which the statements are made. These statements involve a number
of risks and uncertainties. Any forward-looking statements that we make
herein and in future reports and statements are not guarantees of future
performance, and actual results may differ materially from those in such
forward-looking statements as a result of various factors relating to our
strategy, outlook and growth prospects, including our operational and
financial targets; the expected growth of the markets in which we operate;
the competitive environment in which we operate; the economic outlook in
general and, in particular, economic conditions in the European and U.S.
markets; growth in demand for our products, increases in the penetration of
our products into their respective markets, reimbursement rates for our
products, or similar measures; and our expansion plans, including planned
expansion into and growth in emerging markets; our ability to gain necessary
regulatory approvals and desirable reimbursement rates for our newly
developed products and technologies; and our ability to market and launch
attractive new product designs and technologies. All forward-looking
statements made in this press release are made as of the date hereof, and the
risk that actual results will differ materially from expectations expressed
herein will increase with the passage of time. The Company undertakes no duty
to publicly update any forward-looking statements, whether as a result of new
information, future events or otherwise.

This announcement is being distributed to and is directed only at (i)
persons who are outside the United Kingdom or (ii) persons who have
professional experience in matters relating to investments falling within
Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (the "Order") and (iii) high net worth entities, and
other persons to whom it may lawfully be communicated, falling within Article
49(2) (a) to (d) of the Order (all such persons together being referred to as
"relevant persons"). Any investment activity to which this communication
relates will only be available to and will only be engaged with, relevant
persons. Any person who is not a relevant person should not act or rely on
this document or any of its contents.

This document is an advertisement for purposes of applicable measures
implementing Directive 2003/71/EC.

This announcement is not an offer to sell or the solicitation of an offer
to buy the new notes in any jurisdiction in which such an offer, solicitation
or sale would be unlawful.

    Media Contact
    Nimisha Savani
    +1-908-904-2522
    nimisha.savani@convatec.com

Nimisha Savani, +1-908-904-2522, nimisha.savani at convatec.com